Reference priceEUR €577.50Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Darzalex Faspro |
|---|---|
| Manufacturer | Janssen Biotech, Inc |
| Prescription required | Yes |
Darzalex Faspro 120mg/2000Units/ml injection,1vials x 15ml (daratumumab/hyaluronidase-fihj)
daratumumab/hyaluronidase-fihj
Description
Darzalex Faspro 120mg/2000Units/ml injection,1vials x 15ml(/) (daratumumab/hyaluronidase-fihj) is a medicine catalog record in the MediPriceHub database. Active ingredient: daratumumab/hyaluronidase-fihj. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Janssen Biotech, Inc. Therapeutic category: Medicine Library > Oncology Medicines > Myeloma (myelofibrosis) drugs. Pack information: 1800 / 30000 / 15 (120 / 2000 / ). Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
DARZALEX is indicated for the treatment of adult patients with multiple myeloma: in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant. in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant. in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy. in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. in combination with pomalidomide and dexamethasone in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.How to Use
Use daratumumab/hyaluronidase-fihj under the supervision of a qualified healthcare professional. It should be prepared and administered only by trained healthcare professionals in a setting appropriate for injectable or infusion medicines. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: daratumumab/hyaluronidase-fihj. Pack size: 1800 / 30000 / 15 (120 / 2000 / ). Pack unit: bottle. Manufacturer: Janssen Biotech, Inc. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Myeloma (myelofibrosis) drugs. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Injectable and infusion products may also cause administration-site pain, swelling, infection, infusion reactions, or hypersensitivity. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.Esta información es solo orientativa. Consulta a un profesional sanitario antes de usar cualquier medicamento.